| Primary |
| Schizophrenia |
38.8% |
| Product Used For Unknown Indication |
16.4% |
| Schizophrenia, Paranoid Type |
6.5% |
| Psychotic Disorder |
5.0% |
| Insomnia |
4.8% |
| Anxiety |
4.4% |
| Drug Use For Unknown Indication |
3.9% |
| Schizoaffective Disorder |
3.2% |
| Depression |
2.6% |
| Bipolar I Disorder |
2.5% |
| Hypertension |
1.7% |
| Bipolar Disorder |
1.4% |
| Lower Limb Fracture |
1.4% |
| Constipation |
1.4% |
| Extrapyramidal Disorder |
1.4% |
| Schizophrenia, Disorganised Type |
1.1% |
| Sleep Disorder |
1.1% |
| Irritability |
0.8% |
| Prophylaxis |
0.8% |
| Cellulitis |
0.7% |
|
| Schizophrenia |
15.5% |
| Psychotic Disorder |
15.3% |
| Suicidal Ideation |
11.5% |
| Suicide Attempt |
9.3% |
| Depression |
6.4% |
| Aggression |
4.8% |
| Completed Suicide |
4.1% |
| Insomnia |
3.6% |
| Weight Increased |
3.6% |
| Mania |
3.3% |
| Delusion |
3.1% |
| Condition Aggravated |
2.6% |
| Treatment Noncompliance |
2.6% |
| Anxiety |
2.4% |
| Death |
2.1% |
| Drug Ineffective |
2.1% |
| Hospitalisation |
1.9% |
| Incorrect Dose Administered |
1.9% |
| Restlessness |
1.9% |
| Vomiting |
1.9% |
|
| Secondary |
| Schizophrenia |
34.4% |
| Product Used For Unknown Indication |
12.6% |
| Schizophrenia, Paranoid Type |
7.0% |
| Schizoaffective Disorder |
6.7% |
| Psychotic Disorder |
6.7% |
| Drug Use For Unknown Indication |
4.8% |
| Anxiety |
4.0% |
| Depression |
3.3% |
| Constipation |
2.9% |
| Insomnia |
2.8% |
| Bipolar I Disorder |
2.5% |
| Schizophrenia, Disorganised Type |
2.4% |
| Hypertension |
2.0% |
| Bipolar Disorder |
1.4% |
| Ill-defined Disorder |
1.2% |
| Mania |
1.2% |
| Lower Limb Fracture |
1.0% |
| Musculoskeletal Pain |
1.0% |
| Sleep Disorder |
1.0% |
| Tourette's Disorder |
1.0% |
|
| Schizophrenia |
18.3% |
| Suicidal Ideation |
14.3% |
| Psychotic Disorder |
12.5% |
| Depression |
6.2% |
| Weight Increased |
5.0% |
| Suicide Attempt |
4.8% |
| Weight Decreased |
4.2% |
| Completed Suicide |
3.7% |
| Mania |
3.7% |
| Pneumonia |
3.5% |
| Drug Ineffective |
3.1% |
| Treatment Noncompliance |
2.9% |
| Condition Aggravated |
2.5% |
| Insomnia |
2.5% |
| Aggression |
2.3% |
| Vomiting |
2.3% |
| Agitation |
2.1% |
| Tremor |
2.1% |
| Akathisia |
1.9% |
| Poor Quality Sleep |
1.9% |
|
| Concomitant |
| Schizophrenia |
34.9% |
| Smoking Cessation Therapy |
9.6% |
| Product Used For Unknown Indication |
8.1% |
| Bipolar Disorder |
6.9% |
| Drug Use For Unknown Indication |
6.7% |
| Depression |
5.8% |
| Insomnia |
3.6% |
| Schizophrenia, Paranoid Type |
3.1% |
| Schizoaffective Disorder |
2.9% |
| Affective Disorder |
2.7% |
| Agitation |
2.2% |
| Anxiety |
2.2% |
| Bipolar I Disorder |
2.0% |
| Aggression |
1.3% |
| Hypersensitivity |
1.3% |
| Hypothyroidism |
1.3% |
| Muscle Rigidity |
1.3% |
| Pain |
1.3% |
| Psychotic Disorder |
1.3% |
| Blood Cholesterol Increased |
1.1% |
|
| Weight Increased |
20.4% |
| Schizophrenia |
18.5% |
| Suicide Attempt |
7.4% |
| Suicidal Ideation |
5.6% |
| Psychotic Disorder |
4.6% |
| Aggression |
3.7% |
| Neutropenia |
3.7% |
| Type 2 Diabetes Mellitus |
3.7% |
| Vomiting |
3.7% |
| White Blood Cell Count Increased |
3.7% |
| Convulsion |
2.8% |
| Illusion |
2.8% |
| Insomnia |
2.8% |
| Liver Disorder |
2.8% |
| Nausea |
2.8% |
| Neuroleptic Malignant Syndrome |
2.8% |
| Therapeutic Product Ineffective |
2.8% |
| Agranulocytosis |
1.9% |
| Antipsychotic Drug Level Below Therapeutic |
1.9% |
| Blood Creatine Phosphokinase Increased |
1.9% |
|
| Interacting |
| Anxiety |
25.0% |
| Product Used For Unknown Indication |
25.0% |
| Depression |
15.0% |
| Insomnia |
10.0% |
| Schizophrenia |
10.0% |
| Suicide Attempt |
10.0% |
| Smoking Cessation Therapy |
5.0% |
|
| Drug Interaction |
25.0% |
| Abnormal Weight Gain |
12.5% |
| Hyperprolactinaemia |
12.5% |
| Nasal Dryness |
12.5% |
| Neutropenia |
12.5% |
| Psychotic Behaviour |
12.5% |
| Sleep Disorder |
12.5% |
|
